Lexicon Pharmaceuticals, Inc. (LXRX)
-NasdaqGS 2.89 
0.51(21.43%) 4:00PM EDT|After Hours
:
2.90 0.01 (0.35%) 7:50PM EDT
| Prev Close: | 2.38 |
|---|
| Open: | 2.86 |
|---|
| Bid: | N/A |
|---|
| Ask: | 4.00 x 100 |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | 2.61 |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | 2.82 - 3.18 |
|---|
| 52wk Range: | 1.55 - 3.18 |
|---|
| Volume: | 11,573,237 |
|---|
| Avg Vol (3m): | 1,094,180 |
|---|
| Market Cap: | 1.48B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Does Lexicon Own the Future of Type 2 Diabetes?at Motley Fool(Tue 3:45PM EDT)
- Why Lexicon Pharmaceuticals Inc. Shares Exploded Higherat Motley Fool(Tue 1:50PM EDT)
- Lexicon surges on diabetes drug study dataAP(Tue 9:46AM EDT)
- On The Fly: Pre-market Moversat theflyonthewall.com(Tue 9:17AM EDT)
- Lexicon soars on kidney-drug dataoptionMONSTER(Tue 8:36AM EDT)
- LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal ImpairmentPR Newswire(Tue 6:50AM EDT)
- InPlay: Lexicon Pharma achieves 'positive' Results in Type 2 Diabetes Patients with Renal Impairment; LX4211 provided clinically meaningful and statistically significant reductionsBriefing.com(Tue 6:01AM EDT)
- LEXICON PHARMACEUTICALS, INC./DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial StatementsEDGAR Online(Thu, Sep 19)
- Matthew Lehman, the CEO of Prima BioMed Ltd. (PBMD), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Sep 13)
- Lexicon Pharmaceuticals' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)at Seeking Alpha(Wed, Sep 11)
- Lexicon To Present At The Stifel Nicolaus Healthcare ConferencePR Newswire(Fri, Sep 6)
- Lexicon To Present At The Morgan Stanley Global Healthcare ConferencePR Newswire(Thu, Sep 5)
- 3 Reasons Why Clinical Trials Failat Motley Fool(Thu, Aug 29)
- LEXICON PHARMACEUTICALS, INC./DE FinancialsEDGAR Online Financials(Thu, Aug 8)
- Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access ConferencePR Newswire(Wed, Aug 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1,049.84 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 0.59 |
|---|
Business Summary
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has comple...
View More